tiprankstipranks
AddLife AB Class B (ADDLF)
OTHER OTC:ADDLF

AddLife AB (ADDLF) Price & Analysis

11 Followers

ADDLF Stock Chart & Stats

$16.81
$0.00(0.00%)
At close: 4:00 PM EDT
$16.81
$0.00(0.00%)

Bulls Say, Bears Say

Bulls Say
Strong Free Cash Flow GenerationConsistently high free-cash-flow conversion and strong operating cash flow create durable internal funding for capex, working capital and returns. This strengthens resilience versus revenue swings, supports disciplined M&A and debt paydown, and preserves strategic optionality over the next 2–6 months.
Improving Leverage And Balance-sheet CapacityMeaningful net-debt reduction and sub-target leverage provide a durable buffer against downturns and enable disciplined bolt-on acquisitions in the EUR 10–30m turnover range. Stronger balance sheet enhances financial flexibility for capex, working-capital management and opportunistic deals over coming months.
Recurring Consumables And Service-led Revenue MixA high share of consumables, maintenance and service income creates predictable repeat revenue and higher lifetime value per installed system. That structural mix cushions cyclicality from instrument sales and supports margin stability and cash conversion across procurement cycles for the medium term.
Bears Say
Inconsistent Revenue Growth And Volatile ProfitabilitySharp top-line swings and uneven profit recovery reduce earnings visibility and make margin targets harder to sustain. With revenue drivers mixed, shortfalls in instrument or geographic demand can quickly erode operating leverage, complicating planning for investments and M&A over the next few quarters.
Cyclicality And End‑market Softness For InstrumentsDependence on higher-ticket instrument cycles exposes revenue to academic, pharma and elective-procedure spending swings. End‑market hesitancy and procedure disruptions can cause multi-quarter volatility in capital sales, making topline recovery and margin expansion uneven despite recurring revenue buffers.
Divestments And Portfolio Pruning Reduced Recurring SalesActive portfolio shaping and a recent divestment materially trimmed recurring revenue in the near term. While such moves can raise long-term margins, they lower short-term sales predictability and require time and M&A or organic wins to replace lost volumes, pressuring growth metrics in coming quarters.

AddLife AB News

ADDLF FAQ

What was AddLife AB Class B’s price range in the past 12 months?
AddLife AB Class B lowest stock price was $11.75 and its highest was $24.52 in the past 12 months.
    What is AddLife AB Class B’s market cap?
    AddLife AB Class B’s market cap is $2.05B.
      When is AddLife AB Class B’s upcoming earnings report date?
      AddLife AB Class B’s upcoming earnings report date is Apr 28, 2026 which is in 14 days.
        How were AddLife AB Class B’s earnings last quarter?
        AddLife AB Class B released its earnings results on Feb 04, 2026. The company reported $0.231 earnings per share for the quarter, beating the consensus estimate of $0.193 by $0.038.
          Is AddLife AB Class B overvalued?
          According to Wall Street analysts AddLife AB Class B’s price is currently Overvalued. Get more investment ideas with TipRanks Premium
            Does AddLife AB Class B pay dividends?
            AddLife AB Class B pays a Annually dividend of $0.079 which represents an annual dividend yield of 0.2%. See more information on AddLife AB Class B dividends here
              What is AddLife AB Class B’s EPS estimate?
              AddLife AB Class B’s EPS estimate is 0.21.
                How many shares outstanding does AddLife AB Class B have?
                AddLife AB Class B has 117,877,460 shares outstanding.
                  What happened to AddLife AB Class B’s price movement after its last earnings report?
                  AddLife AB Class B reported an EPS of $0.231 in its last earnings report, beating expectations of $0.193. Following the earnings report the stock price went same 0%.
                    Which hedge fund is a major shareholder of AddLife AB Class B?
                    Currently, no hedge funds are holding shares in ADDLF
                    What is the TipRanks Smart Score and how is it calculated?
                    Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

                      Company Description

                      AddLife AB Class B

                      AddLife AB (publ), together with its subsidiaries, provides equipment, medical devices, and reagents primarily to healthcare system, research, colleges, and universities, as well as the food and pharmaceutical industries. The company operates in two segments, Labtech and Medtech. The Labtech segment offers products, solutions, and services in the areas of diagnostics, and biomedical research and laboratory equipment for haematology, pathology, point-of-care diagnostics, cell biology, genetics, microbiology, virology, molecular biology, clinical chemistry, immunology, consumables, and analytical instruments segments. This segment also offers support, maintenance, advice, and training services. The Medtech segment provides medical device products for surgery, respiration, intensive care, wound care, enteral nutrition, fall prevention, welfare technology, ear, and nose and throat segments, as well as bathroom-related assistive devices and assistive devices for children with disabilities. It operates in Sweden, Finland, Denmark, Norway, the United Kingdom, Ireland, Germany, Italy, Austria, Switzerland, rest of Europe, and internationally. AddLife AB (publ) was founded in 1906 and is based in Stockholm, Sweden.

                      AddLife AB (ADDLF) Earnings & Revenues

                      ADDLF Company Deck

                      ADDLF Earnings Call

                      Q4 2026
                      0:00 / 0:00
                      Earnings Call Sentiment|Positive
                      The call conveyed a generally positive tone: clear and continuous margin improvement, strong operating cash flow, meaningful net-debt reduction (net debt-to-EBITDA 2.2), and an active, disciplined M&A pipeline. These positives offset material near-term headwinds from currency effects, some weaker instrument and geographic pockets, and one-off impacts from strikes and a divestment/hand-over of a UK endoscopy business. Management emphasized ongoing margin initiatives, portfolio upgrades and confidence in picking up acquisition activity in 2026.View all ADDLF earnings summaries
                      Similar Stocks
                      Company
                      Price & Change
                      Follow
                      Elekta AB
                      Vitrolife AB
                      BONESUPPORT HOLDING AB
                      Paxman AB
                      Vimian Group AB

                      Ownership Overview

                      11.16%84.73%
                      Insiders
                      ― Other Institutional Investors
                      84.73% Public Companies and
                      Individual Investors

                      Options Prices

                      Currently, No data available
                      ---
                      Popular Stocks